Vyxeos
Showing 1 - 25 of 41
iN the Real Practice
Not yet recruiting
- Acute Myeloid Leukemia (AML)
- +2 more
- Vyxeos liposomal
-
Roma, ItalyPoliclinico Tor Vergata
Nov 16, 2023
Leukemia, Myeloid, Acute Trial in Jerusalem (Vyxeos, Mylotarg)
Recruiting
- Leukemia, Myeloid, Acute
- Vyxeos
- Mylotarg
-
Jerusalem, Yerushalayim, IsraelShaare Zedek Medical Center
Oct 25, 2022
Acute Myeloid Leukemia With FLT3/ITD Mutation Trial in Tampa (Gilteritinib, Vyxeos)
Suspended
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- Gilteritinib
- Vyxeos
-
Tampa, FloridaMoffitt Cancer Center
Nov 11, 2022
Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Tampa (CPX-351)
Active, not recruiting
- Lymphoid Leukemia
- +3 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Dec 30, 2022
Acute Myeloid Leukemia Trial in Tianjin ((cytarabine: daunorubicin) liposome for injection, Vyxeos)
Not yet recruiting
- Acute Myeloid Leukemia
- (cytarabine: daunorubicin) liposome for injection
- Vyxeos
-
Tianjin, ChinaInstitute of Hematology and Hospital of Blood Disease, Chinese A
Mar 24, 2023
Leukemia Trial in Cincinnati (Vyxeos, Venetoclax)
Suspended
- Leukemia
- Vyxeos
- Venetoclax
-
Cincinnati, OhioCincinnati Children's Hospital Medical Center
Sep 21, 2022
Leukemia, Myeloid, Acute Trial in United States (CPX-351, Quizartinib)
Terminated
- Leukemia, Myeloid, Acute
-
Denver, Colorado
- +4 more
May 10, 2022
Acute Myeloid Leukemia, Myelodysplastic Tumor Trial (Magrolimab, 7+3, CPX-351)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Neoplasm
- Magrolimab
- +2 more
- (no location specified)
Apr 24, 2023
Acute Myeloid Leukemia Trial in Tampa (Vyxeos, Gemtuzumab Ozogamicin)
Recruiting
- Acute Myeloid Leukemia
- Vyxeos
- Gemtuzumab Ozogamicin
-
Tampa, FloridaMoffitt Cancer Center
Sep 23, 2022
Acute Myeloid Leukemia (AML) in Remission Trial in Washington (CPX-351)
Recruiting
- Acute Myeloid Leukemia (AML) in Remission
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
May 3, 2022
Acute Myeloid Leukemia Trial in Tianjin (Daunorubicin Cytarabine liposome for injection, Vyxeos?Daunorubicin Cytarabine liposome
Unknown status
- Acute Myeloid Leukemia
- Daunorubicin Cytarabine liposome for injection
- Vyxeos、Daunorubicin Cytarabine liposome for injection
-
Tianjin, ChinaInstitute of Hematology and Hospital of Blood Disease, Chinese A
Jun 7, 2021
Acute Myeloid Leukaemia, Myelodysplasia Trial in Birmingham (Vyxeos, Fludarabine, Busulphan)
Recruiting
- Acute Myeloid Leukaemia
- Myelodysplasia
- Vyxeos
- +4 more
-
Birmingham, United KingdomQueen Elizabeth Hospital
Oct 14, 2021
Acute Myeloid Leukemia Trial in United States (CPX-351, Venetoclax, Midostaurin)
Active, not recruiting
- Acute Myeloid Leukemia
- CPX-351
- +3 more
-
Duarte, California
- +9 more
Jan 3, 2023
Acute Myeloid Leukemia Trial in New York (CPX-351, Gemtuzumab Ozogamicin)
Recruiting
- Acute Myeloid Leukemia
- CPX-351
- Gemtuzumab Ozogamicin
-
New York, New YorkWeill Cornell Medical College
Dec 21, 2021
Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia Trial in Chapel
Recruiting
- Acute Myeloid Leukemia
- +5 more
- Biospecimen Collection
- +3 more
-
Baltimore, Maryland
- +2 more
Jan 19, 2023
Recurrent Acute Myeloid Leukemia Trial in United States (Enasidenib Mesylate, Liposome-encapsulated Daunorubicin-Cytarabine)
Suspended
- Recurrent Acute Myeloid Leukemia
- Enasidenib Mesylate
- Liposome-encapsulated Daunorubicin-Cytarabine
-
Los Angeles, California
- +3 more
Sep 27, 2022
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk
Recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +5 more
- Gemtuzumab Ozogamicin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
A Post-Marketing Observational Study of VYXEOS™
Completed
- Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Therapy-Related Acute Myeloid Leukemia
-
Indianapolis, Indiana
- +6 more
Aug 4, 2020